ABI-4334 shows strong antiviral activity and favorable safety in Phase 1b study for chronic HBV, with data expected in 2025. ABI-4334 demonstrated strong antiviral activity with a mean reduction of ...
Assembly Biosciences, Inc., a biotechnology company developing innovative therapeutics targeting serious viral diseases, announced encouraging interim safety, pharmacokinetic (PK) and efficacy results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results